Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Front Immunol ; 14: 1142723, 2023.
Article in English | MEDLINE | ID: mdl-37304263

ABSTRACT

Autoimmune diseases are skewed toward one biological sex or another. This is the obvious observation of many decades, and it remains unexplained. Females predominate with most autoimmune diseases. The reasons for this predilection are an interplay of genetic, epigenetic and hormonal factors.


Subject(s)
Autoimmune Diseases , Autoimmunity , Female , Male , Humans
2.
Curr Opin Rheumatol ; 35(2): 117-127, 2023 03 01.
Article in English | MEDLINE | ID: mdl-35797514

ABSTRACT

PURPOSE OF REVIEW: As perspectives on sex and gender identity have evolved, there has been an increase in the practice of transgender medicine. Within rheumatology, however, there is a dearth of information about rheumatic disease in transgender and gender diverse (TGGD) individuals. This is important, as sex hormones affect the etiopathogenesis and expression of autoimmune diseases. We therefore sought to identify TGGD patients with rheumatic disease, review their clinical courses, and appraise existing literature about this population. RECENT FINDINGS: Of 1053 patients seen at the Los Angeles County and University of Southern California Medical Center from 2019 through 2021, five transgender men and two transgender women with rheumatic disease were identified. Most patients' disease courses were not overtly impacted by gender affirming hormone therapy (GAHT). Six of seven patients had psychosocial barriers to care. Our systematic review found 11 studies with 11 transgender women and two transgender men. In 12 of 13 patients, GAHT possibly modulated the patients' rheumatic disease. SUMMARY: Our observations suggest GAHT need not be a strict contraindication in TGGD patients with rheumatic disease. TGGD patients often face significant psychosocial barriers. Additional information about this population and empathy toward their health disparities are needed.


Subject(s)
Rheumatic Diseases , Transgender Persons , Humans , Female , Male , Transgender Persons/psychology , Gender Identity , Rheumatic Diseases/complications , Rheumatic Diseases/drug therapy
3.
Lupus ; 29(8): 892-912, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32486934

ABSTRACT

OBJECTIVE: Rituximab (RTX) has important usage in rheumatoid arthritis and vasculitis. There remains a need for more, better, and safer treatments for patients with lupus nephritis (LN). RTX has been trialed in such patients without definitive conclusions about its effectiveness. As a role for RTX has not been clearly established for LN, we carried out a systematic review and analysis. METHODS: We identified 31 studies of RTX for class I-VI LN, and assessed complete renal response (CRR) and partial renal response (PRR) using criteria including serum creatinine, proteinuria, and urinary sediment. Due to differences in the pediatric presentation of the disease, studies focusing on pediatric patients were excluded. RESULTS: One randomized controlled trial (RCT) showed superiority of RTX+cyclophosphamide (CYC) versus CYC alone (64% vs. 21% CRR and 19% vs. 36% PRR). Six prospective and retrospective studies utilizing RTX monotherapy found 66% CRR or PRR in all patients. Eleven studies that investigated RTX in combination with CYC or mycophenolate mofetil (MMF) also found 66% CRR or PRR in all patients. In total, the CRR for Caucasian, East Asian, and Hispanic patients were 77%, 38%, and 28%, respectively. CONCLUSIONS: RTX appeared to benefit certain LN patients, but most studies were not randomized or properly controlled, were heterogeneous in design, subjects, and LN types, and were not comparable, and must therefore be interpreted cautiously. RTX alone may not deplete B cells sufficiently for the perturbations of LN. In addition, RTX may induce responses differently among patients of different ethnic and racial backgrounds. Furthermore, there were wide variations in the baseline characteristics of the patients, namely LN class, time course of disease, age, and prior immunosuppressive use. We suggest a prospective RCT in patients aged 18-65 years with class IV LN. Ideally, the patients would not have received prior immunosuppression and would better represent different ethnicities. The treatment groups would be RTX, RTX+belimumab, CYC, and MMF groups, with pulse-dose steroids during induction followed by maintenance steroids and MMF. The CRR and PRR would be assessed at 12 and 24 months. This or a similar study might clarify RTX's role in the treatment of LN.


Subject(s)
Immunosuppressive Agents/therapeutic use , Lupus Nephritis/drug therapy , Rituximab/therapeutic use , Cyclophosphamide/therapeutic use , Drug Therapy, Combination , Humans , Kidney/drug effects , Lupus Nephritis/mortality , Mycophenolic Acid/therapeutic use , Randomized Controlled Trials as Topic , Remission Induction/methods , Treatment Outcome
4.
Am J Med Sci ; 360(1): 72-74, 2020 07.
Article in English | MEDLINE | ID: mdl-32448501

ABSTRACT

Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is an X-linked genetic disorder associated with intravascular hemolysis. Rhabdomyolysis with myoglobinuria in a patient with G6PD deficiency is a very rare manifestation, in fact, to the best of our knowledge, only a few case reports have been published in the literature to date. Herein, we report an unusual presentation of a 33-year-old male with G6PD deficiency with multiple episodes of severe rhabdomyolysis with no significant concurrent hemolysis. This case supports the hypothesis that rhabdomyolysis may be a rare manifestation of G6PD deficiency, though the exact causation still remains unclear.


Subject(s)
Glucosephosphate Dehydrogenase Deficiency/complications , Rhabdomyolysis/etiology , Rhabdomyolysis/pathology , Adult , Fluid Therapy , Glucosephosphate Dehydrogenase Deficiency/therapy , Humans , Male
5.
Clin Immunol ; 172: 98-100, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27546447

ABSTRACT

Immunoendocrinology or the study of the effects of sex steroids and sex chromatin on immune diseases was pioneered by Henry G. Kunkel. In the disease lupus (SLE) the prevalence of female disease is high; the sex ratio is 10 females to every male after puberty. Since Kunkel's death the influences of triggering epitopes like viruses, histocompatibility, the hypothalamic pituitary-adrenocortical axis, nervous system and the effect of sex steroids are all recognized as contributing factors to pathogenesis. It is too simple to say that sex and genetics are the final reason for the female predominance of SLE. Today the likely cause of the disease involves the epigenetics of sex chromatin and the factors detailed above.


Subject(s)
Lupus Erythematosus, Systemic/immunology , Androgens/immunology , Animals , Estrogens/immunology , Humans
6.
Nat Rev Rheumatol ; 10(2): 97-107, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24166241

ABSTRACT

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with substantial clinical heterogeneity. Current treatments for SLE are effective at reducing morbidity and mortality but fail to provide a cure, and they frequently have adverse effects. Traditional treatments include NSAIDs and antimalarial agents, which are the first-line therapies for mild SLE. In addition, glucocorticoids and cytotoxic or immunosuppressive agents--such as azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine and methotrexate--are used for SLE with organ involvement. Advances in understanding the immunopathogenesis of SLE have led to the development of targeted immunotherapies, such as the anti-BAFF antibody belimumab, which has been approved as an add-on therapy for patients who have active disease despite receiving standard therapy. This Review presents an overview of the current therapies and nonpharmacological management approaches for SLE, and discusses the best approaches for treating specific disease manifestations such as lupus nephritis, neuropsychiatric lupus and cutaneous lupus erythematosus.


Subject(s)
Lupus Erythematosus, Systemic/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antimalarials/therapeutic use , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Immunotherapy
7.
Saudi Med J ; 34(9): 887-95, 2013 Sep.
Article in English | MEDLINE | ID: mdl-24042998

ABSTRACT

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with significant clinical heterogeneity. Its pathogenesis is complex and involves multigenic components, dysregulation of T and B lymphocytes and the presence of autoantibodies, which form the basis for inflammation, and the pathology found in the various organ systems. Traditional treatments for SLE have included non-steroidal anti-inflammatory drugs, antimalarials, corticosteroids, and cytotoxic/immunosuppressants, but a recent emphasis on the development of biological agents that inhibit autoreactive B cells, interrupt cytokine signaling and facilitate the development of regulatory T cells has become a new modality in treating the disease. This review will delve into the pathogenesis of the disease process, as well as the current and up and coming novel biological treatment and other therapies for specific disease manifestations, such as neuropsychiatric SLE and cutaneous lupus erythematosus, and detail the shift to immune targeted therapies and novel treatments being developed for specific manifestations of the disease.


Subject(s)
Lupus Erythematosus, Systemic/therapy , Autoantibodies/immunology , Humans , Lupus Erythematosus, Systemic/immunology
9.
Am J Emerg Med ; 29(4): 396-400, 2011 May.
Article in English | MEDLINE | ID: mdl-20825810

ABSTRACT

PURPOSES: We performed this study to assess the impact of pre-hospital time on the patient's outcome. PROCEDURES: Starting from the symptoms onset, "total time to treatment" was divided into less than or equal to 120 minutes and more than 120 minutes ("pre-hospital time" of ≤ or > 30 minutes respectively). Adverse patient's outcomes were compared in the two subgroups. FINDINGS: Our patients had a mean age of 63 (±13) years. On-scene time (17.8 ± 9.4 minutes), was the biggest fraction of "pre-hospital time". Comparing the groups with "Total time to treatment" of >120 minutes vs. ±120 minutes ("pre-hospital time" of >30 vs. ≤30 minutes), mortalities were 4 vs. 0 and transfers to a tertiary care facility were 3 vs.1. CONCLUSIONS: Most of the pre-hospital time in STEMI was spent on the scene and we suggest "total time to treatment" as a core measure instead of "door to balloon time".


Subject(s)
Emergency Medical Services/organization & administration , Myocardial Infarction/therapy , Aged , Angioplasty, Balloon, Coronary , Cohort Studies , Electrocardiography , Female , Humans , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/mortality , Retrospective Studies , Survival Rate , Time Factors
10.
Ther Adv Musculoskelet Dis ; 3(5): 255-66, 2011 Oct.
Article in English | MEDLINE | ID: mdl-22870484

ABSTRACT

There are many new therapeutic directions for the disease systemic lupus erythematosus (SLE). Despite this, the US Food and Drug Administration (FDA) has approved only one biological agent and it involves B cells, now thought to play a significant role in the pathogenesis of SLE. The name of the drug is belimumab, which is an agent that removes the B-cell cytokine called B lymphocyte stimulation factor (BLyS). Rituximab did not achieve its primary endpoints, even though the consensus is that it may be effective in some forms of SLE including renal disease. The anticytokine therapies against interleukin (IL)-6, IL-10, IL-17 and tumor necrosis factor (TNF) are effective in their own ways and phase II and III trials are in progress. Of particular interest to immunologists are the anti-interferon alpha and gamma drugs, which show promise in the animal models. Modulation of costimulatory molecules; specifically, the anti CD40, CTLA-***Ig and ICOS/B7RP blockade agents offer possibilities for the future using new pathways heretofore limited to rheumatoid arthritis. Finally, the use of tyrosine kinase inhibitors is another direction that has been successful in the inhibition of SLE in the murine model; early trials in human SLE have begun.

11.
Ann N Y Acad Sci ; 1155: 242-51, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19250211

ABSTRACT

Determination of 2- and 16alpha-hydroxylation of estradiol in patients with a variety of liver disorders using a dynamic method of quantitating the extent of hydroxylation revealed specific and characteristic differences in the metabolic response. Patients with acute or silent variants of hepatitis B had estrogen metabolite patterns that were indistinguishable from those found in the control subjects. Female patients with autoimmune hepatitis (formerly known as lupoid hepatitis), however, showed a moderate significant decrease (P < 0.01) in 2-hydroxylation as compared with normal controls (mean 16.3 +/- 1.9 vs. 33.9 +/- 2.5), with no significant change in 16alpha-hydroxylation. Male and female subjects with chronic alcoholic cirrhosis were almost devoid of 2-hydroxylation (mean 2.9 +/- 0.5, P < 0.01), but did show a significant increase in 16alpha-hydroxylation (P < 0.01). The results, therefore, show that the alterations in patterns of biological oxidation are highly specific and do not reflect a general inability to metabolize estrogens in the cirrhotic patient. However, the results also suggest the possibility that a substantial fraction of 16alpha-hydroxylation may occur elsewhere in the body at sites other than in the liver, explaining why this biotransformation pathway is elevated, while the reaction at C-2 is almost absent in the alcoholic cirrhotic subjects.


Subject(s)
Estradiol/metabolism , Hepatitis B/metabolism , Hepatitis, Autoimmune/metabolism , Liver Diseases/metabolism , Acute Disease , Adult , Chronic Disease , Female , Humans , Hydroxylation , Male , Middle Aged , Oxidation-Reduction
13.
Rheum Dis Clin North Am ; 31(1): 19-27, vii, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15639053

ABSTRACT

Sex hormones seem to play an important role as modulators and perpetuators of rheumatic disorders with autoimmune involvement, such as rheumatoid arthritis or systemic lupus erythematosus. Estrogens are implicated in the immune response as enhancers of the humoral immunity. Sex hormones can exert local actions (paracrine) in the tissues in which they are formed; an accelerated peripheral metabolic conversion of upstream androgen precursors to estrogens has been well-assessed. Local effects of sex hormones in autoimmune rheumatic diseases seem to consist mainly of the modulation of cell proliferation and cytokine production. All of these data further suggest caution in exogenous estrogen administration in patients who have autoimmune diseases.


Subject(s)
Arthritis, Rheumatoid/physiopathology , Estrogens/physiology , Gonadal Steroid Hormones/physiology , Arthritis, Rheumatoid/immunology , Autoimmune Diseases/immunology , Estrogens/adverse effects , Female , Humans , Male
14.
Rheum Dis Clin North Am ; 31(1): 161-75, x, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15639061

ABSTRACT

Much progress has been made in the understanding of the impact of the neuroendocrine immune interactions and the pathogenic role in systemic lupus erythematosus, clinically and at the molecular level. This article focuses on the intertwining networks that involve the hypothalamic-pituitary-adrenal axis, cytokines within the central nervous system, and the sympathetic system. Hormones (estrogen, prolactin, gonadotropin-releasing hormone, and leptin) play an important role as immunomodulatory agents.


Subject(s)
Immune System/physiopathology , Lupus Erythematosus, Systemic/etiology , Neurosecretory Systems/physiopathology , GTP-Binding Proteins/physiology , Hormones/physiology , Humans , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/physiopathology , Stress, Physiological/complications , Stress, Physiological/immunology , Stress, Physiological/physiopathology , Sympathetic Nervous System/physiopathology
15.
Arthritis Rheum ; 50(9): 2858-68, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15452837

ABSTRACT

OBJECTIVE: To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms. METHODS: Women with active SLE were treated with prasterone 200 mg/day plus standard SLE treatments or with placebo plus standard SLE treatments for up to 12 months in this randomized, double-blind investigation conducted at 27 centers. Standard SLE treatments included prednisone (/=6 weeks prior to enrollment and remain unchanged during protocol treatment. Responders were patients who experienced no clinical deterioration and had improvement or stabilization over the duration of the study in 2 disease activity measures (the SLE Disease Activity Index [SLEDAI] and the Systemic Lupus Activity Measure) and 2 quality of life measures (patient's global assessment and the Krupp Fatigue Severity Scale). RESULTS: A total of 381 women with SLE were enrolled. Among patients with clinically active disease at baseline (SLEDAI score >2), 86 of 147 in the prasterone group (58.5%) demonstrated improvement or stabilization without clinical deterioration, as compared with 65 of 146 in the placebo group (44.5%) (P = 0.017). Acne and hirsutism were reported in 33% and 16%, respectively, of the prasterone group and in 14% and 2%, respectively, of the placebo group (P < 0.05 for both comparisons). However, most cases of acne and hirsutism were mild and did not require withdrawal from therapy. Myalgias and oral stomatitis were reported less frequently in the prasterone group (22% and 15%, respectively) than in the placebo group (36% and 23%, respectively) (P < 0.05 for both comparisons). Serum levels of high-density lipoprotein cholesterol, triglycerides, and C3 complement significantly decreased, while levels of testosterone and, to a lesser extent, estradiol increased in the prasterone group. CONCLUSION: In adult women with active SLE, administration of prasterone at a dosage of 200 mg/day improved or stabilized signs and symptoms of disease and was generally well tolerated.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Dehydroepiandrosterone/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Adult , Double-Blind Method , Female , Humans , Prospective Studies , Severity of Illness Index , Treatment Outcome
17.
J Rheumatol ; 30(11): 2374-81, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14677180

ABSTRACT

OBJECTIVE: To analyze the performance of different commercial enzyme immunoassay (EIA) kits for measuring antinuclear antibodies (ANA) specific for dsDNA, SSB/La, Sm, and Scl-70. METHODS: EIA kits for detection of ANA from 9 commercial manufacturers were evaluated. The manufacturers were advised that they would be sent coded sera containing mixtures of the Arthritis Foundation/Centers for Disease Control reference reagents, and that they were to use their own test kits to analyze the antibody specificities of these sera and to report the data, in optical density (OD) units or their equivalent. Independently, 12 investigators in academic institutions who have done research in this field agreed to participate in a parallel study. The concentration of the antibodies and the specificities were blinded to the analysts and the coefficients of variation (CV) were computed for each participant. RESULTS: There were statistically significant differences between laboratories in terms of CV for all 9 kits tested. With the exception of one kit, there were no significant CV differences between the various autoantibody kits provided by each manufacturer and, with the exception of kits from 2 manufacturers, there were no significant differences between the various antibody kits in terms of reproducibility (CV). From the point of view of interlaboratory variability, manufacturers could be separated into either a high or low performance group. CONCLUSION: We found a disconcertingly large range of performance characteristics in the various laboratories, which could be quite detrimental in routine utilization of EIA ANA kits. Clinicians should be aware of the performance issues raised in our study, and should know and be involved in how their service laboratory assesses its own performance and the performance of commercial testing systems utilized. Manufacturers and clinical laboratories need to exercise constant quality assurance and surveillance of kit performance in the hands of medical laboratory technologists involved in routine testing.


Subject(s)
Antibodies, Antinuclear/analysis , Immunoenzyme Techniques/standards , Reagent Kits, Diagnostic/standards , Analysis of Variance , Antibody Specificity , Drug Industry , Humans , Laboratories , Reproducibility of Results , Sensitivity and Specificity , Single-Blind Method , Universities
19.
Arthritis Rheum ; 46(5): 1133-5, 2002 May.
Article in English | MEDLINE | ID: mdl-12115213
20.
Arthritis Rheum ; 46(7): 1820-9, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12124866

ABSTRACT

OBJECTIVE: To evaluate whether treatment with prasterone (dehydroepiandrosterone [DHEA]) would allow the dosage of prednisone (or an equivalent corticosteroid) to be reduced to < or = 7.5 mg/day for 2 months or longer while maintaining stable or reduced disease activity in steroid-dependent women with systemic lupus erythematosus (SLE). METHODS: In a double-blind, randomized trial, 191 female SLE patients receiving prednisone (10-30 mg/day) were treated daily with either placebo, 100 mg of oral prasterone (an adrenal androgen), or 200 mg of oral prasterone for 7-9-months. At monthly intervals, corticosteroid dosages were reduced by algorithm in patients whose SLE Disease Activity Index (SLEDAI) score was stable or improved. Patients for whom a sustained reduction in the dosage of prednisone (< or = 7.5 mg/day) was achieved for at least the last 2 months of the 7-9-month treatment period were classified as responders. RESULTS: Response rates were 41% in the placebo group, 44% in the 100-mg prasterone group, and 55% in the 200-mg group (P = 0.110, 200 mg versus placebo). Among the 137 subjects (45 in the placebo group, 47 in the 100-mg group, and 45 in the 200-mg group) who had active disease at baseline (defined as SLEDAI score >2), 29%, 38%, and 51%, respectively, were responders (P = 0.031 for 200 mg prasterone versus placebo). Acne was the most common adverse event but was generally mild. Clinical and laboratory changes primarily reflected androgenic effects of prasterone. CONCLUSION: Among women with lupus disease activity, reducing the dosage of prednisone to < or = 7.5 mg/day for a sustained period of time while maintaining stabilization or a reduction of disease activity was possible in a significantly greater proportion of patients treated with oral prasterone, 200 mg once daily, compared with patients treated with placebo.


Subject(s)
Adrenal Cortex Hormones/administration & dosage , Dehydroepiandrosterone/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Administration, Oral , Adolescent , Adult , Dehydroepiandrosterone/administration & dosage , Dehydroepiandrosterone/adverse effects , Double-Blind Method , Female , Humans , Multicenter Studies as Topic , Prednisolone/administration & dosage , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...